Epredia, a developer of cancer and tissue diagnostics, and Lunaphore Technologies, a developer of next-generation equipment for cancer research based in Lausanne, Switzerland, have entered into a distribution agreement, according to a press release from Epredia.
This follows the announcement of a strategic investment in Lunaphore by PHC Holdings Corporation, the parent company of Epredia, which was announced on February 6, 2020.
Under the terms of this agreement, Epredia has been appointed the exclusive distributor of the LabSat Research platform in the United States, United Kingdom and Germany, and it will begin distributing the product to these countries in July 2020. In addition, Epredia will begin distributing the LabSat Research platform in Japan in 2021. The platform will be available for research use only in these four countries.
Epredia will also provide service for the Lunaphore instruments.
The LabSat Research platform is an automated tissue-staining instrument for rapid immunohistochemistry (IHC) and immunofluorescence (IF). It utilizes a microfluidic technology for rapid and uniform delivery of reagents to tissue samples. This enables accurate staining with improved protocol turnaround time.
